Business
Roadman Investments Clarifies Prior Disclosures Regarding CLOV BioPharma Corp.
(via TheNewswire) VANCOUVER, British Columbia - TheNewswire - March 30, 2020 ...
About this update from Futuregen Industries Corp.
[{"type":"text","content":"Roadman Investments Clarifies Prior Disclosures Regarding CLOV BioPharma Corp.(via TheNewswire)\n \n \nVANCOUVER, British Columbia - TheNewswire - March 30, 2020 - Roadman Investments Corp. (TSXV:LITT) (FWB:1QD) (OTC:RMANF) (\"Roadman\" or the \"Company\") at the request of the TSX Venture Exchange, wishes to clarify the disclosures in its news release disseminated by the Company on March 11, 2020 with respect to research and development activities by the Company or its Subsidiary CLOV BioPharma Corp. (\"CBP\") and the disclosures in its news release dated March 26, 2020 with respect to the recent amendment to the license agreement (as amended, the \"InMicro License Agreement\") between CBP and inMicro Indoor Air Inc. (\"inMicro\").\n\n\n \nThe Company's news release dated March 11, 2020 contained the statement \"The mission of CLOV Biopharma Corp. is to conduct further research and development of cedar leaf oil vapour for the purposes of preventing the spread of Coronavirus and other similar potentially pathogenic respiratory viruses, for example, influenza and para-influenza viruses, and respiratory syncytial virus.\"\n\n \n \nThe Company would like to clarify that the language \"further research and development\" was intended to convey CBP's plan to make inquiries into having additional research and development conducted based on prior research completed by Dr. Hudson on the effectiveness of CLOV. Previously published peer reviewed journals authored by Dr. Hudson concluded that, in a laboratory setting, CLOV was effective in killing (inactivating) several human respiratory viruses, including Influenza virus, Rhinovirus, Adenovirus, as well as Herpes simplex virus. It was also shown that short-term exposure to CLOV had no adverse effect on cultured lung epithelial cells, thus indicating that it is not cytotoxic. Further, it was shown that CLOV also partly reversed the pro-inflammatory effect caused by Rhinovirus infection, which means that it acts as a multifunctional therapeutic agent. 12\n\n \n \nThe Company wishes the further clarify that the Company, CBP and Dr. Hudson have not conducted any research to date with respect to CLOV's impact prevention of the Coronavirus. The Company has not conducted in-house research and development and has no plans to conduct any in-house research and development. The Company has made inqui...